In a multicentre observational study of 22 patients with adult-onset IgA vasculitis, 90.9% (n = 20) achieved remission (as defined by Birmingham Vasculitis Activity Score; BVAS) at an average follow-up of 24 months when receiving rituximab either as monotherapy or as an additional therapy. Following the initiation of rituximab, patients experienced reductions in BVAS (P < 0.0001) and levels of proteinuria (P < 0.0001) and C-reactive protein (P = 0.0005), and were able to reduce their dose of prednisone. Of those patients who achieved remission, 35% (n = 7) subsequently experienced a relapse.